MAP2K7 and neoplasm: In support of the in vitro results, MEK inhibition with trametinib substantially suppressed tumor growth in MESO-1 and patient-derived xenograft (PDX) models without apparent toxicities in mice (Fig. 1H; Fig. S1F, G).